HSP90 Inhibitors: Current Development and Potential in Cancer Therapy

ISSN: 2212-3970 (Online)
ISSN: 1574-8928 (Print)


Volume 9, 3 Issues, 2014


Download PDF Flyer




Recent Patents on Anti-Cancer Drug Discovery

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 96th of 261 in Pharmacology & Pharmacy
  • 92nd of 197 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Khurshid Zaman
Bentham Science Publishers
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.7
5 - Year: 2.475

HSP90 Inhibitors: Current Development and Potential in Cancer Therapy

Author(s): Katerina Sidera and Evangelia Patsavoudi

Affiliation: Dept. of Biochemistry, Hellenic Pasteur Institute, 127, Vas. Sofias Av., 11521 Athens, Greece.

Abstract

In the last decade, the molecular chaperone HSP90 has emerged as an important target in cancer therapeutics and has subsequently become the focus of several drug discovery and development efforts. The first-in-class HSP90 inhibitor 17-AAG entered into Phase I clinical trial in 1999. Today 13 HSP90 inhibitors representing multiple drug classes, with different modes of action, are undergoing clinical evaluation. The present review will highlight the involvement of HSP90 in regulating and maintaining the transformed phenotype, provide an overview on current HSP90 inhibitors and further update on the most relevant patents which have recently appeared in the literature.

Keywords: Cancer therapeutics, cell surface, chaperoning, drug discovery, HSP90, signal transduction.

Download Free Rights and Permissions

Article Details

Volume: 9
Issue Number: 1
First Page: 1
Last Page: 20
Page Count: 20
DOI: 10.2174/15748928113089990031
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science